These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4644642)

  • 41. Pharmacokinetics and metabolism of alpha-acetyldigoxin in man.
    Bodem G; Wirth K; Gernand E; Dengler HJ
    Arch Int Pharmacodyn Ther; 1974 Mar; 208(1):102-16. PubMed ID: 4846188
    [No Abstract]   [Full Text] [Related]  

  • 42. Bioavailability of digoxin tablets.
    Lindenbaum J
    Pharmacol Rev; 1973 Jun; 25(2):229-37. PubMed ID: 4581042
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparative bioavailabilities from truncated blood level curves.
    Lovering EG; McGilveray IJ; McMillan I; Tostowaryk W
    J Pharm Sci; 1975 Sep; 64(9):1521-4. PubMed ID: 1185570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissimilarities of digoxin.
    Goldfinger SE
    N Engl J Med; 1971 Dec; 285(24):1376-7. PubMed ID: 5121194
    [No Abstract]   [Full Text] [Related]  

  • 45. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calculating absorption rate constants for drugs with incomplete availability.
    Leeson LJ; Weintraub H
    J Pharm Sci; 1973 Dec; 62(12):1936-41. PubMed ID: 4762161
    [No Abstract]   [Full Text] [Related]  

  • 47. [Biological availability].
    Weber E; Gundert-Remy U
    Arzneimittelforschung; 1975 Jul; 25(7a):1158-62. PubMed ID: 1242346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of physical and animal models to assess bioavailability.
    Barr WH
    Pharmacology; 1972; 8(1):55-101. PubMed ID: 4630161
    [No Abstract]   [Full Text] [Related]  

  • 49. The rabbit as an experimental model for biopharmaceutical studies following rectal administration of theophylline.
    Van Aerde P; Moerman E; Van Severen R; Braeckman P
    Pharmazie; 1984 Mar; 39(3):171-2. PubMed ID: 6728890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intramuscular injections and bioavailability.
    Tuttle CB
    Am J Hosp Pharm; 1977 Sep; 34(9):965-8. PubMed ID: 333911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum-digoxin concentrations with a new digoxin derivative, beta-methyl-digoxin.
    Härtel G; Manninen V; Melin J; Apajalahti A
    Ann Clin Res; 1973 Apr; 5(2):87-90. PubMed ID: 4748756
    [No Abstract]   [Full Text] [Related]  

  • 53. Determination of ADME and bioavailability following intravenous, oral, and dermal routes of exposure.
    Saghir SA
    Curr Protoc Toxicol; 2009 Aug; Chapter 5():Unit 5.8. PubMed ID: 22714106
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Studies on the absorption and activity onset of -mehyl-digoxin in patients with atrial fibrillation].
    Limbourg P; Just H; Fiegel P; Michaelis J; Rosellen E
    Arzneimittelforschung; 1973 Jan; 23(1):60-3. PubMed ID: 4740697
    [No Abstract]   [Full Text] [Related]  

  • 55. [Biologic availability of drugs in humans and animals].
    Wichliński L
    Pol Tyg Lek; 1975 Dec; 30(50):2111-2. PubMed ID: 1197106
    [No Abstract]   [Full Text] [Related]  

  • 56. Evidence for variable digoxin absorption as estimated by pharmacological response intensities.
    Schoenwald RD
    J Pharm Sci; 1974 Mar; 63(3):411-6. PubMed ID: 4820373
    [No Abstract]   [Full Text] [Related]  

  • 57. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination.
    Schumacher GE
    Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265
    [No Abstract]   [Full Text] [Related]  

  • 58. The absorption of digoxin tablets.
    Binnion PF
    Clin Pharmacol Ther; 1974 Nov; 16(5 Part 1):807-12. PubMed ID: 4426149
    [No Abstract]   [Full Text] [Related]  

  • 59. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacokinetic methods for the evaluation of intestinal absorption].
    Kübler W
    Z Kinderheilkd; 1970; 108(3):187-96. PubMed ID: 5475029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.